The Impact of Expanded Testing for Multidrug Resistant Tuberculosis Using Geontype MTBDRplus in South Africa: An Observational Cohort Study

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Hanrahan, Colleen F ^a,b   Dorman, Susan E ^c   Erasmus, Linda ^d   Koornhof, Hendrik ^d   Coetzee, Gerrit ^d   Golub, Jonathan E ^b,c  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b The University of North Carolina at Chapel Hill   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CIPROFLOXACIN; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; PYRAZINAMIDE; RIFAMPICIN; TERIZIDONE;

ADULT; ANALYTICAL EQUIPMENT; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM IDENTIFICATION; CLINICAL EXAMINATION; COHORT ANALYSIS; DISEASE DURATION; FEMALE; GENOTYPING TECHNIQUE; HUMAN; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; OBSERVATIONAL STUDY; PREVALENCE; RETREATMENT; SOUTH AFRICA; SPUTUM CULTURE;

ADULT; ANTITUBERCULAR AGENTS; BACTERIAL TYPING TECHNIQUES; COHORT STUDIES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; ISONIAZID; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; RIFAMPIN; SOUTH AFRICA; SURVIVAL ANALYSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 84870587504     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049898     Document Type: Article

References (20)

1. WHO (2010) Multidrug and extensively drug-resistant TB (M/XDR-TB), 2010 global report on surveillance and response. Geneva, Switzerland.
2. WHO (2011) Global Tuberculosis Control. Geneva.
3. Dowdy DW, Chaisson RE, Maartens G, Corbett EL, Dorman SE, (2008) Impact of enhanced tuberculosis diagnosis in South Africa: a mathematical model of expanded culture and drug susceptibility testing. Proc Natl Acad Sci U S A 105: 11293-11298.
4. Grandjean L, Moore DA, (2008) Tuberculosis in the developing world: recent advances in diagnosis with special consideration of extensively drug-resistant tuberculosis. Curr Opin Infect Dis 21: 454-461.
5. Ling DI, Zwerling AA, Pai M, (2008) GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis. Eur Respir J 32: 1165-1174.
6. Barnard M, Albert H, Coetzee G, O'Brien R, Bosman ME, (2008) Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am J Respir Crit Care Med 177: 787-792.
7. WHO (2008) Molecular line probe assays for rapid screening of patients at risk of multi-drug resistant tuberculosis (MDR-TB). Geneva, Switzerland.
8. Department of Health (2004) The South African national tuberculosis control programme practical guidelines. Pretoria, South Africa.
9. Enarson DA, Rieder HL, Arnadottir TA (2000) Management of tuberculosis: a guide for low income countries. Paris, France: IUATLD.
10. Department of Health (2009) South African national tuberculosis managment guidelines. Pretoria, South Afirca.
11. Becton Dickinson (2010) BBL MGIT Mycobacteria growth indicator tube 7 mL with BACTEC MGIT 960 supplement kit manual. 1-4.
12. Becton Dickinson (2002) BACTEC MGIT 960 SIRE kit product insert.
13. Hain LifeScience GMBH (2009) GenoType MTBDRplus product insert (version 1.0).
14. WHO (2008) Guidelines for the programmatic management of drug-resistant tuberculosis: emergency update. Geneva, Switzerland.
15. Crudu V, Stratan E, Romancenco E, Allerheiligen V, Hillemann A, et al. (2012) First evaluation of an improved assay for molecular genetic detection of tuberculosis as well as rifampin and isoniazid resistances. J Clin Microbiol 50: 1264-1269.
16. Meyer-Rath G, Schnippel K, Long L, MacLeod W, Sanne I, et al. (2012) The impact and cost of scaling up GeneXpert MTB/RIF in South Africa. PLoS One 7: e36966.
17. WHO (2011) Policy statement: automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system. Geneva, Switzerland.
18. Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, et al. (2011) Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 377: 1495-1505.
19. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, et al. (2010) Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 363: 1005-1015.
20. Lawn SD, Kerkhoff AD, Wood R (2012) Location of Xpert(R) MTB/RIF in centralised laboratories in South Africa undermines potential impact. Int J Tuberc Lung Dis 16: 701; author reply 702.